Immix Biopharma (IMMX) Other financing activities (2021 - 2025)
Quarterly results put Other financing activities at $602109.0 for Q1 2025, down 2.24% from a year ago — trailing twelve months through Mar 2025 was $2.4 million (up 6.74% YoY), and the annual figure for FY2024 was $2.4 million, up 23.15%.
Immix Biopharma has reported Other financing activities over the past 5 years, most recently at $602109.0 for Q1 2025.
- Other financing activities reached $602109.0 in Q1 2025 per IMMX's latest filing, down from $613153.0 in the prior quarter.
- Across five years, Other financing activities topped out at $737325.0 in Q3 2023 and bottomed at $4247.0 in Q1 2021.
- Median Other financing activities over the past 5 years was $329919.0 (2023), compared with a mean of $334214.3.
- The largest annual shift saw Other financing activities surged 1432.23% in 2022 before it fell 14.72% in 2024.
- Over 5 years, Other financing activities stood at $122152.0 in 2021, then skyrocketed by 88.37% to $230094.0 in 2022, then soared by 86.18% to $428385.0 in 2023, then surged by 43.13% to $613153.0 in 2024, then fell by 1.8% to $602109.0 in 2025.
- Business Quant data shows Other financing activities for IMMX at $602109.0 in Q1 2025, $613153.0 in Q4 2024, and $628806.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 602,109.00 |
| Mar 31, 2025 | 602,109.00 |
| Dec 31, 2024 | 613,153.00 |
| Dec 31, 2024 | 613,153.00 |
| Sep 30, 2024 | 628,806.00 |
| Sep 30, 2024 | 628,806.00 |
| Jun 30, 2024 | 535,350.00 |
| Jun 30, 2024 | 535,350.00 |
| Mar 31, 2024 | 615,888.00 |
| Mar 31, 2024 | 615,888.00 |
| Dec 31, 2023 | 428,385.00 |
| Dec 31, 2023 | 428,385.00 |
| Sep 30, 2023 | 737,325.00 |
| Sep 30, 2023 | 737,325.00 |
| Jun 30, 2023 | 447,656.00 |
| Jun 30, 2023 | 447,656.00 |
| Mar 31, 2023 | 329,919.00 |
| Mar 31, 2023 | 329,919.00 |
| Dec 31, 2022 | 230,094.00 |
| Dec 31, 2022 | 230,094.00 |
| Sep 30, 2022 | 163,192.00 |
| Sep 30, 2022 | 163,192.00 |
| Jun 30, 2022 | 65,709.00 |
| Jun 30, 2022 | 65,709.00 |
| Mar 31, 2022 | 65,074.00 |
| Mar 31, 2022 | 65,074.00 |
| Dec 31, 2021 | 122,152.00 |
| Dec 31, 2021 | 122,152.00 |
| Sep 30, 2021 | 61,860.00 |
| Sep 30, 2021 | 61,860.00 |
| Jun 30, 2021 | 30,724.00 |
| Jun 30, 2021 | 30,724.00 |
| Mar 31, 2021 | 4,247.00 |
| Mar 31, 2021 | 4,247.00 |